期刊文献+

原发性肝癌发生与ras基因突变的关系 被引量:11

Relationship between primary liver cancer and ras gene mutation
原文传递
导出
摘要 目的探讨H.ras、K-ras、N—ras基因突变与原发性肝癌发生发展的关系。方法采用HotStarTaq聚合酶链反应(PCR)检测32例原发性肝癌组织中H—ras、K—Fas、N-ras基因的表达并采用PCR直接测序分析H—ras、K-ras、N—tab基因突变私检验检测H-ras突变与临床病理的关系。结果在32例原发性肝癌组织中均可检测到H—ras、K-ras、N—ras基因的表达,32例原发性肝癌标本PCR结果经测序后,17例标本发现H-ras基因发生突变(17/32,53.1%),14例40密码子中A突变成G,3例62密码子中G突变成A。K—ras、N-ras基因未发生突变,H-ras突变与肿瘤转移有关。结论H-ras基因异常表达与肝癌相关,可能导致了原发性肝癌的发生。 Objective To investigate the association between mutation of H-ras, K-ras, N-ras and carcinogenesis of primary liver cancer (PLC). Methods HotStarTaq polymerase chain reaction (PCR) was used to detect the expression of H-ras, K-ras, N-ras gene in 32 PLC patientds and the mutation of H- ras, K-ras, N-ras gene was analyzed by PCR and direct sequencing. Results The expression of H-ras, K- ras, N-ras was detected in 32 cases. Sequencing indicates that H-ras mutation occur in 17 cases, among which 14 cases was verified to be a A/G transition in codon 40 and 3 cases G/A transition in codon 62. K- ras, N-ras had no mutation. H-ras mutation was correlated to tumor metastasis. Conclusion Abnormal expression of H-ras is correlated with PLC and may lead to the the carcinogenesis of PLC.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2012年第3期438-440,共3页 Chinese Journal of Experimental Surgery
关键词 原发性肝癌 HotStarTaq聚合酶链反应 RAS 测序 Primary liver cancer HotStarTaq polymerase chain reaction ras Sequencing
  • 相关文献

参考文献3

二级参考文献8

  • 1Zhang T,Ma J,Cao X.Grb2 regulates STAT3 activation negatively in epidermal growth factor signalling.Biochem J,2003,376:457-464.
  • 2Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science,2004,304:1497-1500.
  • 3Pao W,Wang TY,Riely GJ,et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.PLoS Med,2005,2:57-60.
  • 4Mascaux C,Iannino N,Martin B,et al.The role of PAS oncogene in survival of patients with lung cancer:a systematic review of the literature with meta-analysis.Br J Cancer,2005,92:131-139.
  • 5Han SW,Kim TY,Jeon YK,et al.Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation,K-ras mutation,and Akt phosphorylation.Clin Cancer Res,2006,12:2538-2544.
  • 6Eberhard DA,Johnson BE,Amler LC,et al.Mutations in the epidermal growth factor receptor and in KPAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.J Clin Oncol,2005,23:5900-5909.
  • 7Yue Y,Lypowy J,Hedhli N,et al.Ras GTPase-activating protein binds to AKT and is required for its activation.J Biol Chem,2004,279:12883-12889.
  • 8杨帆,陈克终,隋锡朝,李剑锋,王俊,姜冠潮.K-Ras突变对表皮生长因子受体抑制剂敏感细胞株的影响[J].中华实验外科杂志,2010(1):96-97. 被引量:8

共引文献14

同被引文献91

引证文献11

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部